AGÕæÈ˹ٷ½

STOCK TITAN

Agenus SEC Filings

AGEN NASDAQ

Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Analyzing Agenus Inc.’s immuno-oncology disclosures can feel like decoding lab notebooks—hundreds of pages packed with trial endpoints, milestone payments, and manufacturing risks. If you’ve ever wondered how to locate breakthrough data or track executive stock sales before a catalyst, you’re not alone.

Stock Titan delivers AI-powered summaries that turn every Agenus SEC document into plain English. Whether you need the Agenus quarterly earnings report 10-Q filing for burn-rate analysis, an Agenus 8-K material events explained alert on new clinical results, or Agenus insider trading Form 4 transactions to monitor buying and selling, our platform updates in real time as soon as EDGAR posts.

Here’s how investors use it:

  • Receive push notifications for Agenus Form 4 insider transactions real-time and spot buying patterns.
  • Dive into an Agenus annual report 10-K simplified view that highlights cash runway, collaboration revenue, and cGMP manufacturing commitments.
  • Compare pipeline progress across quarters with succinct Agenus earnings report filing analysis.
  • Access the latest Agenus proxy statement executive compensation details without sifting through appendices.

Every filing�10-K, 10-Q, 8-K, S-1, and more—is indexed, searchable, and paired with concise expert context, ensuring understanding Agenus SEC documents with AI is straightforward. No more scrolling through dense scientific jargon; the critical insights are surfaced for you.

Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Dimensional Fund Advisors LP (DFA) has filed a Schedule 13G indicating that, as of 30 June 2025, it beneficially owns 1,572,330 shares of Boston Omaha Corp ("BOC"), representing 5.1 % of the company’s outstanding common stock. The institutional investor reports sole voting power over 1,540,879 shares and sole dispositive power over the full 1,572,330-share position, with no shared voting or dispositive authority.

DFA, a Delaware limited partnership and SEC-registered investment adviser, explains that the shares are held across multiple mutual funds, commingled trusts and separate accounts for which it or its subsidiaries act as adviser or sub-adviser. While DFA may exercise voting and investment discretion, it expressly disclaims beneficial ownership in excess of the requirements of Section 13(d).

Crossing the 5 % ownership threshold triggers this disclosure and signals a modest increase in institutional ownership in BOC. Because DFA is predominantly a passive, quantitative manager, the filing does not suggest an activist agenda or an intention to influence control. Nevertheless, additional institutional sponsorship can enhance liquidity, broaden research coverage and potentially support the share price through index-related demand.

Key numeric details

  • Date of event: 30 June 2025
  • Shares owned: 1,572,330
  • Percent of class: 5.1 %
  • Sole voting power: 1,540,879
  • Sole dispositive power: 1,572,330

Overall, the Schedule 13G is an informative but routine ownership disclosure that underscores growing passive interest in Boston Omaha without materially altering corporate governance or near-term strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Dimensional Fund Advisors LP (DFA) has filed a Schedule 13G indicating that, as of 30 June 2025, it beneficially owns 1,572,330 shares of Boston Omaha Corp ("BOC"), representing 5.1 % of the company’s outstanding common stock. The institutional investor reports sole voting power over 1,540,879 shares and sole dispositive power over the full 1,572,330-share position, with no shared voting or dispositive authority.

DFA, a Delaware limited partnership and SEC-registered investment adviser, explains that the shares are held across multiple mutual funds, commingled trusts and separate accounts for which it or its subsidiaries act as adviser or sub-adviser. While DFA may exercise voting and investment discretion, it expressly disclaims beneficial ownership in excess of the requirements of Section 13(d).

Crossing the 5 % ownership threshold triggers this disclosure and signals a modest increase in institutional ownership in BOC. Because DFA is predominantly a passive, quantitative manager, the filing does not suggest an activist agenda or an intention to influence control. Nevertheless, additional institutional sponsorship can enhance liquidity, broaden research coverage and potentially support the share price through index-related demand.

Key numeric details

  • Date of event: 30 June 2025
  • Shares owned: 1,572,330
  • Percent of class: 5.1 %
  • Sole voting power: 1,540,879
  • Sole dispositive power: 1,572,330

Overall, the Schedule 13G is an informative but routine ownership disclosure that underscores growing passive interest in Boston Omaha without materially altering corporate governance or near-term strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Redwire Corp (RDW) â€� Form 4 insider filing: Chief Accounting Officer Chris Edmunds reported an automatic share withholding transaction on 1 July 2025 related to the vesting of restricted stock units (Transaction Code F, tax liability settlement).

  • Securities disposed: 1,298 common shares at the closing price of $15.31.
  • Post-transaction ownership: Edmunds now holds 96,956 common shares directly.
  • Nature of transaction: Withholding for taxes is generally considered non-discretionary and does not indicate a change in sentiment.

No derivative securities were involved, and no open-market purchases or sales were recorded. The size of the withholding represents a small fraction of the insider’s total ownership and is unlikely to be market-moving.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Netcapital Inc. (Nasdaq: NCPL) filed an 8-K reporting that on 26 June 2025 it entered into a Horizon Software Agreement with Switzerland-based Horizon Globex GmbH. Horizon granted Netcapital a royalty-free, paid-up, non-exclusive, perpetual and irrevocable license to use Horizon’s capital-raising and secondary-trading software under the Company’s own branding in the United States.

As consideration, Netcapital will issue 500,0000 shares of its common stock (the “Horizon Shares�) to Horizon or its affiliate. The shares will be issued without registration under Sections 4(a)(2) and/or 3(a)(9) of the Securities Act, and no cash will be received by the Company.

The agreement includes standard termination rights: (i) either party may terminate after a 30-day cure period for material breach, and (ii) immediate termination is permitted upon bankruptcy, receivership, dissolution, or cessation of business of the other party. The full contract is attached as Exhibit 10.1.

This transaction gives Netcapital long-term access to a trading technology platform that could expand its service offering, but it also introduces equity dilution and execution risk should the software fail to drive revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Willis Lease Finance Corp. (WLFC) � Form 144/A filing reports a proposed insider sale.

  • Shares to be sold: 7,295 common shares.
  • Estimated market value: $1,058,573.15 (based on information supplied in the filing).
  • Broker: Merrill Lynch, 77 Broad Street, Red Bank, NJ 07701.
  • Approximate sale date: 06/27/2025 on the NASDAQ.
  • Shares outstanding: 6,902,975, so the proposed sale equals roughly 0.11 % of total shares.
  • Acquisition details: Shares were acquired on 04/01/2024 through stock compensation.
  • Recent prior sales: The seller (identified in the filing as Brian Hole, 30 White Pine Lane, West Hartford, CT 06107) sold 2,893 shares on 05/27/2025 for $386,744.40 and 2,807 shares on 05/23/2025 for $368,973.16, indicating a continuing disposition program.

The filing contains the customary representation that the seller is not aware of undisclosed material adverse information. No other financial or operational data is included.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Willis Lease Finance Corp. (WLFC) � Form 144/A filing reports a proposed insider sale.

  • Shares to be sold: 7,295 common shares.
  • Estimated market value: $1,058,573.15 (based on information supplied in the filing).
  • Broker: Merrill Lynch, 77 Broad Street, Red Bank, NJ 07701.
  • Approximate sale date: 06/27/2025 on the NASDAQ.
  • Shares outstanding: 6,902,975, so the proposed sale equals roughly 0.11 % of total shares.
  • Acquisition details: Shares were acquired on 04/01/2024 through stock compensation.
  • Recent prior sales: The seller (identified in the filing as Brian Hole, 30 White Pine Lane, West Hartford, CT 06107) sold 2,893 shares on 05/27/2025 for $386,744.40 and 2,807 shares on 05/23/2025 for $368,973.16, indicating a continuing disposition program.

The filing contains the customary representation that the seller is not aware of undisclosed material adverse information. No other financial or operational data is included.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Agenus (Nasdaq: AGEN) filed an 8-K detailing the results of its 17 June 2025 Annual Meeting, where 16.71 million shares�61.5 % of shares outstanding—were represented.

Board elections: Class I directors Brian Corvese (5.99 m for / 4.83 m withheld) and Timothy Wright (6.86 m for / 3.96 m withheld) were elected to serve until 2028.

Equity & compensation matters:

  • Stockholders approved expanding the 2019 Equity Incentive Plan to 12.05 m shares, adding 7.0 m shares (6.14 m for / 4.59 m against / 0.08 m abstain).
  • They approved raising share limits on the Directorsâ€� Deferred Compensation Plan (+25 k shares) and the 2019 ESPP (+50 k shares).
  • A one-time option exchange was rejected (4.87 m for / 5.82 m against).
  • The advisory say-on-pay resolution was also rejected (5.16 m for / 5.18 m against).

Audit: KPMG LLP was ratified for FY 2025 (13.62 m for / 2.87 m against).

The voting pattern shows notable shareholder resistance to current compensation practices—even as additional share reserves for future equity awards were endorsed—signalling potential governance scrutiny ahead.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Agenus (NASDAQ: AGEN) filed a Form 4 disclosing that director Timothy Wright received a total of 15,750 stock options on 06/17/2025 under the company’s 2019 Amended & Restated Equity Incentive Plan.

The options carry an exercise price of $3.02 and expire on 05/28/2035. Two tranches were awarded: 750 options that vest one-third on 05/28/2026 and quarterly thereafter, and 15,000 options that vest fully one year after the grant date. All awards were reported as directly held; no shares were sold or otherwise disposed. The filing is a routine disclosure of director compensation rather than a change in ownership of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Form 4 Filing Overview � Agenus Inc. (AGEN)

Director Susan B. Hirsch reported the receipt of 15,000 non-qualified stock options under the company’s 2019 Amended & Restated Equity Incentive Plan. The grant was originally approved on 28 May 2025, became effective upon shareholder approval at the 17 June 2025 annual meeting, and is therefore shown as the transaction date. Key terms are:

  • Exercise price: $3.02 per share
  • Vesting: 100 % on the one-year anniversary of the grant date (28 May 2026)
  • Expiration: 28 May 2035 (10-year term)
  • Post-transaction holdings: 15,000 derivative securities (stock options) held directly

No purchases or sales of Agenus common stock were reported, and no non-derivative holdings changed. The filing therefore represents a routine equity award intended to align director incentives rather than an open-market transaction that would signal confidence or concern about near-term fundamentals. At approximately 15 k shares, potential dilution is de-minimis relative to Agenus� outstanding share count.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Agenus (AGEN)?

The current stock price of Agenus (AGEN) is $5.96 as of July 25, 2025.

What is the market cap of Agenus (AGEN)?

The market cap of Agenus (AGEN) is approximately 166.4M.

What is Agenus Inc primarily focused on?

Agenus Inc is focused on developing immunotherapy treatments by leveraging the body’s immune system. Its primary research areas include immune-modulatory antibodies, checkpoint modulators, and vaccine adjuvants.

How does Agenus generate its revenue?

Agenus operates as a clinical-stage biopharmaceutical company, advancing a broad pipeline of therapies through collaborations and licensing agreements while focusing on strategic clinical development.

What are the key platform technologies used by Agenus?

The company utilizes proprietary antibody platforms, including Retrocyte Display� and SECANT®, along with advanced cell therapy and vaccine adjuvant platforms to drive its immunotherapy pipeline.

How does Agenus differentiate itself in the competitive biotech landscape?

Agenus differentiates itself through its integrated approach combining rigorous scientific research, proprietary technologies, and in-house cGMP manufacturing, which together ensure high-quality therapy development.

What market segments does Agenus operate within?

Agenus operates primarily in the immuno-oncology and biotechnology sectors, focusing on the development of therapies for challenging cancers and infectious diseases.

Is Agenus involved in cell therapy development?

Yes, through its subsidiary initiatives, Agenus is actively involved in developing adoptive cell therapies, which complement its broader pipeline of immuno-oncology solutions.

How does Agenus ensure quality and regulatory compliance?

The company maintains in-house cGMP manufacturing facilities and a robust clinical operations platform to ensure that all therapies meet stringent quality and regulatory standards.

What challenges does Agenus face in the development of immunotherapies?

Developing novel immunotherapies involves overcoming significant clinical and regulatory challenges, including extensive validation of efficacy, ensuring patient safety, and navigating a competitive research landscape.
Agenus

NASDAQ:AGEN

AGEN Rankings

AGEN Stock Data

166.42M
26.89M
1.31%
33.81%
13.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LEXINGTON